Skip to content

Study · Not a test of the peptide alone · 2005

3 results

Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso.

Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Wüst K, Walter-Sack I, Mikus G and 5 more

Show all authors

Burhenne J, Riedel KD, Schirmer H, Kouyaté B, Müller O

Tropical medicine & international health : TM & IH1 Jan 2005Cited by 42 (Europe PMC)

PMID15655011 (opens in a new tab)DOI10.1111/j.1365-3156.2004.01356.x (opens in a new tab)PepBankPUB-15655011
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Methylene blue was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Methylene blue.

  1. 01HumanNot a test of Methylene blue aloneNon-randomized trialSafety outcome

    In G6PD-deficient healthy adult men, haemolysis did not occur during chloroquine-methylene blue treatment.

    In plain wordsIn G6PD-deficient healthy adult men, no red blood cell breakdown occurred during chloroquine-methylene blue treatment.

    Peptide
    Methylene blue
    Outcome
    Not applicableHaemolysis
    Study

    n = 74

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Haemolysis did not occur, haemoglobin levels remained stable or even rose in the study participants, and the drug regimen was well tolerated.
    1 context sentence
    Summary · context
    Against this background, 74 G6PD-deficient but otherwise healthy adult men were given a 3-day oral regimen of a total of 1500 mg CQ and 780 mg MB in the District Hospital of Nouna in north-western Burkina Faso.

    In this study, Methylene blue was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Methylene blue.

  2. 02HumanNot a test of Methylene blue aloneNon-randomized trialSafety outcome

    In G6PD-deficient healthy adult men, haemoglobin stayed stable or rose during chloroquine-methylene blue treatment.

    In plain wordsIn G6PD-deficient healthy adult men, haemoglobin stayed stable or rose compared with baseline during chloroquine-methylene blue treatment.

    Peptide
    Methylene blue
    Outcome
    MixedHaemoglobin
    Study

    n = 74

    Comparator
    Baseline
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Haemolysis did not occur, haemoglobin levels remained stable or even rose in the study participants, and the drug regimen was well tolerated.
    1 context sentence
    Summary · context
    Against this background, 74 G6PD-deficient but otherwise healthy adult men were given a 3-day oral regimen of a total of 1500 mg CQ and 780 mg MB in the District Hospital of Nouna in north-western Burkina Faso.

    In this study, Methylene blue was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Methylene blue.

  3. 03HumanNot a test of Methylene blue aloneNon-randomized trialSafety outcome

    In G6PD-deficient healthy adult men, the chloroquine-methylene blue regimen was well tolerated.

    In plain wordsIn G6PD-deficient healthy adult men, the chloroquine-methylene blue regimen was well tolerated.

    Peptide
    Methylene blue
    Outcome
    Not applicableTolerability
    Study

    n = 74

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Haemolysis did not occur, haemoglobin levels remained stable or even rose in the study participants, and the drug regimen was well tolerated.
    1 context sentence
    Summary · context
    Against this background, 74 G6PD-deficient but otherwise healthy adult men were given a 3-day oral regimen of a total of 1500 mg CQ and 780 mg MB in the District Hospital of Nouna in north-western Burkina Faso.

    In this study, Methylene blue was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Methylene blue.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.